Engineered t cells take on deadly childhood brain cancer
NCT ID NCT05478837
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new treatment for children and young adults with a rare, aggressive brain tumor called H3.3K27M-mutated diffuse midline glioma. The treatment involves taking a patient's own immune cells (T cells), genetically modifying them in the lab to recognize the tumor, and giving them back after a short course of chemotherapy. The main goals are to see if the treatment is safe and to find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified T cells (KIND T cells) plus chemotherapy (cyclophosphamide and fludarabine)
What this could lead to
If it works, this could point toward a new treatment option for a rare and aggressive brain tumor that currently has few effective therapies.
What could go wrong
This is a very early, small phase 1 trial with only 12 participants, so it is primarily testing safety and dosing. The treatment may not shrink tumors or improve survival, and there are risks from the chemotherapy and the modified cells themselves.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States